ClinicalTrials.gg
CompletedNCT06015308HYDROUpdated Aug 10, 2026

A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo

A Phase 2 interventional study of Amlitelimab and Placebo in Dermatitis Atopic, sponsored by Sanofi. Completed at 57 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2025, 1 year 1 month ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Aug 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
224
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing amlitelimab in Dermatitis, Atopic — none open to participants now, 4 under way, 3 of them phase 3. amlitelimab · Dermatitis, Atopic.

Enrollment
9th of 11
224 · median 589
Started
2023
with 3 others
Phase 2
4 of 11
none open now
Registered
5th of 11
by date
Lead sponsor
9 of 11
Sanofi

Among the 11 studies testing amlitelimab in Dermatitis, Atopic, this one is the 9th largest by enrollment, is one of 4 that started in 2023, is one of 4 in phase 2, and was the 5th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

None of the 11 studies testing amlitelimab in Dermatitis, Atopic is open now. The open studies under Dermatitis, Atopic, anywhere →

About amlitelimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing amlitelimab in Dermatitis, Atopic as a file.
02

Study summary

This is a Phase 2, multicenter, randomized, double-blind placebo controlled, 2-arm study to evaluate the effect of amlitelimab on vaccine antibody responses, and the safety of amlitelimab concurrently administered with non-live vaccines in adult participants with moderate-to-severe atopic dermatitis (AD).

The purpose of this study is to compare the immune responses to concomitantly administered Boostrix (tetanus, diphtheria, and acellular pertussis [Tdap]) and Pneumovax 23 (PPSV) vaccines in adult participants with moderate-to-severe AD treated with amlitelimab versus placebo. The study will evaluate the percentage of participants achieving a positive anti-tetanus response at Week 16 (primary endpoint) and a positive anti-pneumococcal response at Week 16 (key secondary endpoint).

Study details include:

The study duration will be up to 36 weeks (for participants not entering the LTS17367 [RIVER-AD]).

The screening period will be 9 days to 4 weeks. The treatment duration will be up to 16 weeks. The post-treatment safety follow-up period will be16 weeks. The number of visits will be up to 7 (or 6 for those entering LTS17367 [RIVER-AD]).

Read the detailed description

The study duration will be up to 36 weeks

03

Conditions studied

  • Dermatitis Atopic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be 18 years of age (when signing form)
  • Diagnosis of AD for at least 1 year (defined by the American Academy of Dermatology Consensus Criteria)
  • Documented history (within 6 months before screening) of either inadequate response or inadvisability to topical treatments
  • Validated Investigator Global Assessment scale for atopic dermatitis (vIGA-AD) of 3 or 4 at baseline visit
  • Eczema area and severity index (EASI) score of 12 or higher at baseline
  • AD involvement of 10% or more of body surface area (BSA) at baseline
  • Able and willing to comply with requested study visits and procedures
  • Body weight ≥40 kg and ≤150 kg

Exclusion criteria

Exclusion Criteria:

  • Skin co-morbidity that would adversely affect the ability to undertake AD assessments
  • Receipt of any vaccine (expect influenza and COVID-19 vaccines) within 3 months prior to screening
  • Receipt of any pneumococcal vaccine within approximate timeframe of 5 years prior to screening
  • Prior receipt of two or more doses of Pneumovax 23 at any time
  • Receipt of any tetanus-, diphtheria-, or pertussis-containing vaccine within approximate timeframe of 5 years prior to screening
  • Participants for whom administration of the pneumococcal vaccine provided in this study is or medically inadvisable, according to local label of the vaccine
  • Participants for whom administration of the tetanus, diphtheria, and pertussis vaccine provided in this study is contraindicated or medically inadvisable, according to local label of the vaccine
  • Having received any of the specified therapy within the specified timeframe(s) prior to the baseline visit
  • Known history of or suspected significant current
  • Any or history of malignancies prior to baseline (excluding non-melanoma skin cancer excised and cured >5 years prior to baseline)
  • History of solid organ or stem cell transplant
  • Any active or chronic infection including helminthic infection requiring systemic treatment within 2 weeks prior baseline
  • Positive for (HIV), or at screening visit
  • Participants with active tuberculosis (TB), latent TB, a history of incompletely treated TB, suspected extrapulmonary TB infection, or who are at high risk of contracting TB

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
224 participants (actual)

Study arms

  • Experimental
    Amlitelimab

    Participants will receive amlitelimab and vaccines as per protocol.

    Drug: Amlitelimab · Biological: Tdap vaccine · Biological: PPS vaccine

  • Placebo comparator
    Placebo

    Participants will receive placebo matching amlitelimab and vaccines as per protocol.

    Drug: Placebo · Biological: Tdap vaccine · Biological: PPS vaccine

Interventions

  • Subcutaneous injection in abdomen, outer thigh, or upper arm

  • DrugPlacebo

    Subcutaneous injection in abdomen, outer thigh, or upper arm

  • BiologicalTdap vaccine

    Intramuscular (IM) injection into the deltoid muscle of the upper arm

  • BiologicalPPS vaccine

    Intramuscular or subcutaneous injection into the deltoid muscle of the upper arm

06

What researchers measure

Primary outcomes

  1. Percentage of participants with a positive tetanus response at Week 16

    Positive tetanus response is defined as ≥2.5 IU/mL in anti-tetanus immunoglobulin G \[IgG\] titer for participants with a pre-vaccination baseline \[Week 12\] tetanus antibody titer of \>1 IU/mL or a titer ≥ 3-fold increase for participants with a pre-vaccination titer of ≤1IU/mL).

    Time frame: Week 16

Secondary outcomes

  1. Percentage of participants with a positive pneumococcal vaccine response at Week 16

    Positive pneumococcal vaccine response is defined as a ≥2-fold increase from baseline in anti-pneumococcal antibodies (APAb) against \>50% of the 23 serotypes.

    Time frame: Week 16

  2. Percentage of participants who experienced treatment-emergent adverse events (TEAE), including serious adverse events (SAE) and adverse events of special interest (AESI)

    Time frame: Week 0 up to Week 32

  3. Percentage of participants with potentially clinically significant abnormalities (PCSA) for vital signs and clinical laboratory assessments

    Time frame: Week 0 up to Week 32

  4. Percentage of participants discontinued from study treatment due to TEAEs

    Time frame: Week 0 up to Week 32

  5. Proportion of participants with validated Investigator Global Assessment scale for atopic dermatitis (vIGA-AD) of 0 (clear) or 1 (almost clear) and a reduction of ≥2 points from baseline at Week 16

    The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).

    Time frame: Week 16

  6. Proportion of participants with a ≥75% reduction in EASI score (EASI-75) from baseline at Week 16

    The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD using a 4-point scale; 0 (absent) to 3 (severe).

    Time frame: Week 16

  7. Serum amlitelimab concentrations

    Time frame: Week 0 up to Week 16

  8. Incidence of antidrug antibodies (ADAs) of amlitelimab

    Time frame: Week 0 up to Week 16

07

Study locations

57 sites
  • Clinical Research Center of Alabama - Homewood- Site Number : 8401101
    Birmingham, Alabama 35209, United States
  • Center for Dermatology and Plastic Surgery- Site Number : 8401119
    Scottsdale, Arizona 85260, United States
  • Orange County Clinical Trials- Site Number : 8401271
    Anaheim, California 92801, United States
  • First OC Dermatology- Site Number : 8401025
    Fountain Valley, California 92708, United States
  • Center for Dermatology Clinical Research- Site Number : 8401018
    Fremont, California 94538, United States
  • Valley Research- Site Number : 8401097
    Fresno, California 93720, United States
  • Paradigm Clinical Research Centers- Site Number : 8401273
    La Mesa, California 91942, United States
  • Sunwise Clinical Research- Site Number : 8401022
    Lafayette, California 94549, United States
  • Antelope Valley Clinical Trials- Site Number : 8401099
    Lancaster, California 93534, United States
  • Torrance Clinical Research- Site Number : 8401027
    Lomita, California 90717, United States
  • Clinical Science Institute- Site Number : 8401028
    Santa Monica, California 90404, United States
  • Velocity Clinical Research - Denver Site Number : 8401168
    Denver, Colorado 80209, United States
  • Daxia Trials- Site Number : 8401145
    Boca Raton, Florida 33431, United States
  • Encore Medical Research of Boynton Beach- Site Number : 8401030
    Boynton Beach, Florida 33436, United States
  • Alliance for Multispeciality Research - Fort Myers- Site Number : 8401111
    Fort Myers, Florida 33912, United States
  • Doral Medical Research- Site Number : 8401094
    Hialeah, Florida 33016, United States
  • C&R Research Services - Kendall- Site Number : 8401029
    Kendall, Florida 33183, United States
  • Acevedo Clinical Research Associates- Site Number : 8401088
    Miami, Florida 33142, United States
  • Future Care Solution - Miami- Site Number : 8401144
    Miami, Florida 33142, United States
  • Sanchez Clinical Research- Site Number : 8401095
    Miami, Florida 33157, United States
  • Florida International Research Center- Site Number : 8401091
    Miami, Florida 33173, United States
  • Wellness Clinical Research - Miami Lakes- Site Number : 8401109
    Miami Lakes, Florida 33016, United States
  • K2 South Orlando - South Orange Avenue- Site Number : 8401268
    Orlando, Florida 32806, United States
  • SEC Clinical Research- Site Number : 8401270
    Pensacola, Florida 32501, United States
  • Global Clinical Professionals (GCP)- Site Number : 8401045
    St. Petersburg, Florida 33705, United States
  • Clinical Research Trials of Florida- Site Number : 8401023
    Tampa, Florida 33607, United States
  • Paradigm Clinical Research - Boise- Site Number : 8401272
    Boise, Idaho 83709, United States
  • Skin Sciences- Site Number : 8401039
    Louisville, Kentucky 40217, United States
  • Velocity Clinical Research at The Dermatology Clinic- Site Number : 8401072
    Baton Rouge, Louisiana 70809, United States
  • BRCR Global Gretna- Site Number : 8401243
    Gretna, Louisiana 70053, United States
  • Boeson Research - Missoula- Site Number : 8401269
    Missoula, Montana 59804, United States
  • Henderson Clinical Trials- Site Number : 8401169
    Henderson, Nevada 89052, United States
  • Skin Search Rochester- Site Number : 8401216
    Rochester, New York 14623, United States
  • Velocity Clinical Research - Durham- Site Number : 8401175
    Durham, North Carolina 27701, United States
  • Velocity Clinical Research - Springdale- Site Number : 8401153
    Cincinnati, Ohio 45246, United States
  • Velocity Clinical Research - Medford- Site Number : 8401170
    Medford, Oregon 97504, United States
  • Vial Health - DermDox Dermatology- Site Number : 8401031
    Camp Hill, Pennsylvania 17011, United States
  • Velocity Clinical Research - Providence- Site Number : 8401179
    East Greenwich, Rhode Island 02818, United States
  • Velocity Clinical Research - Charleston - Ashley Town Center Drive- Site Number : 8401174
    Charleston, South Carolina 29414, United States
  • Velocity Clinical Research - Columbia- Site Number : 8401176
    Columbia, South Carolina 29204, United States
  • Velocity Clinical Research - Austin- Site Number : 8401173
    Cedar Park, Texas 78613, United States
  • Modern Research Associates- Site Number : 8401093
    Dallas, Texas 75231, United States
  • Heights Dermatology & Aesthetic Center- Site Number : 8401143
    Houston, Texas 77008, United States
  • Dermatology Clinical Research Center of San Antonio- Site Number : 8401100
    San Antonio, Texas 78229, United States
  • Discovery Clinical Trials - San Antonio - Stone Oak Parkway- Site Number : 8401026
    San Antonio, Texas 78258, United States
  • Stryde Research - Epiphany Dermatology- Site Number : 8401185
    Southlake, Texas 76092, United States
  • Ogden Clinic Mountain View (Avacare) Site Number : 8401167
    Pleasant View, Utah 84404, United States
  • Investigational Site Number : 1240019
    Calgary, Alberta T2W 4X9, Canada
  • Investigational Site Number : 1240023
    Calgary, Alberta T3A 2N1, Canada
  • Investigational Site Number : 1240016
    Edmonton, Alberta T5J 3S9, Canada
  • Investigational Site Number : 1240014
    Barrie, Ontario L4M 7G1, Canada
  • Investigational Site Number : 1240020
    Hamilton, Ontario L8L 3C3, Canada
  • Investigational Site Number : 1240017
    London, Ontario N6H 5L5, Canada
  • Investigational Site Number : 1240018
    Newmarket, Ontario L3Y 5G8, Canada
  • Investigational Site Number : 1240024
    Richmond Hill, Ontario L4B 1A5, Canada
  • Investigational Site Number : 1240021
    Toronto, Ontario M2N 3A6, Canada
  • Investigational Site Number : 1240026
    Toronto, Ontario M4E 1R7, Canada
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Oct 2025, 23 months.

Of 195 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 23 months is above that.

Counting every sponsor, half of 223 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2023
First posted
Aug 29, 2023
StartActual
Oct 6, 2023
Primary completionActual
Oct 1, 2025
CompletionActual
Jan 16, 2026
Results delay requested
Aug 6, 2026
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06015308
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Aug 29, 2023
Start date
Oct 6, 2023
Primary completion
Oct 1, 2025
Completion
Jan 16, 2026
Last update
Aug 10, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlitelimab

Start the discussion